SG Americas Securities’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-73,488
| Closed | -$223K | – | 3846 |
|
|
2024
Q4 | $223K | Sell |
73,488
-3,475
| -5% | -$15.1K | ﹤0.01% | 2055 |
|
|
2024
Q3 | $399K | Buy |
+76,963
| New | +$382K | ﹤0.01% | 1890 |
|
|
2024
Q1 | – | Sell |
-62,598
| Closed | -$550K | – | 3546 |
|
|
2023
Q4 | $550K | Buy |
+62,598
| New | +$513K | 0.01% | 1417 |
|
|
2023
Q2 | – | Sell |
-21,549
| Closed | -$694K | – | 3329 |
|
|
2023
Q1 | $694K | Buy |
21,549
+14,087
| +189% | +$439K | 0.01% | 1451 |
|
|
2022
Q4 | $138K | Sell |
7,462
-3,940
| -35% | -$90.1K | ﹤0.01% | 2495 |
|
|
2022
Q3 | $308K | Buy |
+11,402
| New | +$231K | ﹤0.01% | 1970 |
|
|
2021
Q4 | – | Sell |
-33,961
| Closed | -$946K | – | 3882 |
|
|
2021
Q3 | $946K | Buy |
33,961
+26,578
| +360% | +$758K | ﹤0.01% | 1961 |
|
|
2021
Q2 | $219K | Sell |
7,383
-6,610
| -47% | -$191K | ﹤0.01% | 2294 |
|
|
2021
Q1 | $391K | Buy |
13,993
+9,255
| +195% | +$256K | ﹤0.01% | 2185 |
|
|
2020
Q4 | $134K | Sell |
4,738
-44,343
| -90% | -$1.15M | ﹤0.01% | 2885 |
|
|
2020
Q3 | $1.23M | Buy |
49,081
+23,851
| +95% | +$625K | 0.01% | 1058 |
|
|
2020
Q2 | $616K | Buy |
25,230
+15,360
| +156% | +$303K | 0.01% | 1889 |
|
|
2020
Q1 | $146K | Buy |
9,870
+1,944
| +25% | +$40.2K | ﹤0.01% | 2733 |
|
|
2019
Q4 | $129K | Buy |
+7,926
| New | +$123K | ﹤0.01% | 2803 |
|
|
2019
Q2 | – | Sell |
-10,981
| Closed | -$173K | – | 3493 |
|
|
2019
Q1 | $173K | Buy |
+10,981
| New | +$190K | ﹤0.01% | 2669 |
|
|
2017
Q4 | – | Sell |
-5,231
| Closed | -$144K | – | 3717 |
|
|
2017
Q3 | $144K | Buy |
+5,231
| New | +$127K | ﹤0.01% | 2887 |
|
|
2017
Q1 | – | Sell |
-10,734
| Closed | -$222K | – | 3610 |
|
|
2016
Q4 | $222K | Buy |
+10,734
| New | +$180K | ﹤0.01% | 2276 |
|
|
2016
Q2 | – | Sell |
-7,351
| Closed | -$128K | – | 3047 |
|
|
2016
Q1 | $128K | Buy |
+7,351
| New | +$150K | ﹤0.01% | 2477 |
|
|
2015
Q3 | – | Sell |
-3,291
| Closed | -$105K | – | 2795 |
|
|
2015
Q2 | $105K | Buy |
+3,291
| New | +$84.6K | ﹤0.01% | 2345 |
|
Other funds holding RVNC
SG Americas Securities's RVNC Position: Q1 2025 in Review
SG Americas Securities sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 73,488 shares — an estimated $223K sold.
SG Americas Securities first reported a position in RVNC in Q2 2015 and held it in 19 quarters. The position peaked at $1.23M in Q3 2020. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- SG Americas Securities reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- SG Americas Securities sold 73,488 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $223K.
- SG Americas Securities first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 19 quarters.
- SG Americas Securities's Revance Therapeutics, Inc. position peaked at $1.23M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.